TCT-563 Multi-Center, First-In-Man Evaluation of the Myolimus-Eluting Bioresorbable Coronary Scaffold: 6-Month Clinical and Imaging Results  by Verheye, Stefan et al.
TCT-561
Risk Stratification and Outcomes of Patients with Prior Coronary Artery
Stenting Undergoing Noncardiac Surgery
Andrew Goodman1, Michael Chenier2, Kyle Hornsby2, Lindsay Anderson2,
Brett Goodwin2, Kamil Faridi2, Chee Tang Chin3, Tracy Wang2
1Cleveland Clinic, Cleveland, OH, 2Duke University, Durham, NC, 3National
Heart Centre Singapore, Singapore, NC
Background: Little evidence exists to guide risk stratification and management of
patients with prior coronary artery stenting who require noncardiac surgery. While clinical
models for perioperative risk stratification have been established, few studies have
examined angiographic contributors to perioperative risk.
Methods: We examined 405 patients with prior coronary artery stenting who underwent
non-cardiac surgery between 8/23/2001 and 12/27/2009 at a tertiary care institution for
whom detailed information on coronary anatomy and perioperative treatment could be
obtained. Coronary angiograms were independently reviewed, and patients were followed
for a median of 3.1 years after surgery.
Results: In our study population, 52% had prior MI, 18% had prior stroke/TIA, and 26%
had prior heart failure. The median time from PCI to surgery was 325 days (interquartile
range [IQR] 81 to 808). Among these patients, 35% were stented electively, 14% were
stented in the STEMI setting, and 51% were stented in the NSTE ACS setting. Lesions
treated included 18 previously stented lesions, 83 bifurcation lesions, 117 highly calcified
lesions, and 53 lesions with visible thrombus. A total of 188 patients (46%) were treated
with 1 stent, with a median stent diameter of 3mm (IQR 2.5-3) and a median stent
length of 18 mm (IQR 13 to 23). A total of 243 patients (60%) were stented with1 drug
eluting stent (DES). At the time of surgery, 125/220 (57%) patients still on clopidogrel
stopped clopidogrel at a median of 8 days (IQR 5-11) prior to surgery. Among 116 DES
patients undergoing surgery within a year of stent implantation, 37 (32%) stopped
clopidogrel prior to surgery, and 12 (10%) were bridged with a parenteral antithrombotic
agent. Perioperative MI occurred in 19 patients (4.7%). Perioperative bleeding defined as
a preoperative to nadir hematocrit difference 10% occurred in 114 patients (28%) and
transfusions were given in 65 patients (16%). The 3-year mortality risk was 17%.
Conclusions: Patients with coronary disease undergoing noncardiac surgery remain a
high risk population for whom evidence-based strategies are greatly needed to improve
perioperative outcomes.
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Background: Gastrointestinal bleeding (GIB) remains a serious complication for
patients undergoing percutaneous coronary intervention (PCI). Little is known about the
resource utilization and cost for patients with GI bleeding following PCI. We sought to
analyze healthcare resource utilization, cost, and mortality during the study period from
1998-2006 for patients with post-PCI GI bleed.
Methods: The Nationwide Inpatient Sample (NIS), which contains over a hundred
clinical and nonclinical data elements, was analyzed from 1998 to 2006. The primary
analysis was to assess the added hospitalization cost for PCI associated GIB over the study
period. The secondary analysis looked at resource utilization of PCI associated GIB. GIB
was defined as any active bleeding from the upper or lower GI tract. Multivariate linear
regression model was used to adjust for baseline procedure variables. All tests were
2-tailed, with p0.05 considered significant.
Results: There were 1,204.065 patients without GIB and 12,694 (1.04%) with post-PCI
GIB. Post-PCI GIB was associated with increased average hospital cost ($60,094 vs.
$36,758, p0.001) over the study period and increased mortality (6.0% vs. 0.76%,
p0.001) when compared to PCI without GIB. The overall cost increased for both groups
during the study period (p for trend0.001) due to increasing cost of PCI (p0.0001).
The added cost for patients that suffered GIB ($23,336) was secondary to increased need
for blood product administration; FFP ($10,045) and PRBC ($4110), both p0.0001),
and pulmonary artery catheterization ($ 8,612) (p0.0001). Upper and lower endoscopy
did not significantly add to cost for patients with GIB (p0.91).
Conclusions: The overall cost of PCI increased over the study period. PCI-associated
GIB is associated with higher mortality. Incremental costs of GIB are due to blood product
administration and expense associated with hemodynamic monitoring.
Year Cost
No GIB (N) GIB (N)
1998 $23931 (93928) $40790 (931)
1999 $25603 (97027) $43775 (1074)
2000 $27360 (114503) $46705 (1264)
2001 $28519 (137127) $48491 (1568)
2002 $33627 (141957) $56674 (1610)
2003 $38947 (138266) $63707 (1598)
2004 $44101 144479) $70162 (1515)
2005 $47659 (150043) $78981 (1418)
2006 $48197 (169440) $78911 (1505)
Bioresorbable Vascular Scaffolds and
Bioabsorbable Polymers
Hall D
Tuesday, October 23, 2012, 8:00 AM–10:00 AM
Abstract nos: 563-584
TCT-563
Multi-Center, First-In-Man Evaluation of the Myolimus-Eluting Bioresorbable
Coronary Scaffold: 6-Month Clinical and Imaging Results
Stefan Verheye1, Mark Webster2, James Stewart2, Alexandre Abizaid3,
Ricardo Costa4, Jose Costa Jr5, John Yan6, vinayak bhat6, lynn morrison6,
Sara Toyloy6, John Ormiston7
1Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, Antwerp,
Belgium, 2Auckland City Hospital, Auckland, New Zealand, 3Visiting Professor
Columbia University, São Paulo, Brazil, 4INSTITUTO DANTE PAZZANESE DE
CARDIOLOGIA, SAO PAULO, Brazil, 5Instituto Dante Pazzanese de Cardiologia,
São Paulo, Brazil, 6Elixir Medical Corporation, Sunnyvale, CA, 7Associate
Professor, University of Auckland Medical School, Auckland, New Zealand
Background: To evaluate the clinical safety and effectiveness of the DESolve™
Myolimus-Eluting Bioresorbable Coronary Scaffold (BCSS)in patients with single de
novo native coronary artery lesions through clinical endpoints and multiple imaging
modalities. The DESolve BCSS is a novel drug eluting device that combines a
PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug
Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor has demonstrated potent
anti-proliferative properties in two First-in-Man (FIM) trials using Elixir’s metallic
Myolimus-eluting coronary stents. Drug dose is 3 mcg per mm of scaffold length; the
same dose used in the FIM studies.
Methods: Sixteen patients with single, de novo coronary artery lesions were enrolled in
this prospective, multi-center, single-arm FIM study. One patient did not receive a study
stent and was deregistered. The 15 remaining patients are being analysed for multiple
clinical endpoints: Device and Procedure Success; Major Adverse Cardiac Events
(MACE), a composite endpoint of cardiac death, target vessel MI, and clinically-indicated
target lesion revascularization (CI-TLR); clinically-indicated Target Lesion and Target
Vessel Revascularization, (CI-TVR) and stent thrombosis assessed at 1, 6 and 12 months
and annually to 5 years. Multiple assessments by angiographic, IVUS and OCT at 6
months were completed. An additional analysis using multislice computed tomography
(MSCT) will be completed at 12 and 24 months.
Results: At 6 months, the in-scaffold late lumen loss was 0.19  0.19 by QCA, the %
volume obstruction was 7.18 3.37 by IVUS, and by OCT 98.68 2.44% of struts were
demonstrated as covered. There was one MACE event, a TLR, during the follow-up
period. Detailed clinical and imaging results through 6 months will be presented.
Conclusions: The DESolve™ Myolimus-Eluting BCSS demonstrated both excellent
safety and effectiveness in this FIM study, thus warranting further clinical evaluation of
the novel technology in larger clinical studies. Detailed clinical and imaging results
through 6 months will be presented.
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